| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, Gen Counsel & Corp Sec | SVP, Gen Counsel & Corp Sec
1 company
Mikhail Eydelman last filed a Form 4 in March 2025, as SVP, Gen Counsel & Corp Sec at PCVX. Mikhail Eydelman's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Mikhail Eydelman's trades have earned a middling insider score of 67/100 across 18 rated trades. Over a 12-month horizon, 72.2% of those trades were profitable, with an average 12-month return of +26.0%.
At the last filing, the largest reported position was 41,620 shares of PCVX. The PCVX filings lean toward selling, a net 80,503 shares.
Mikhail Eydelman has 27 Form 4 filings on record from May 2022 to March 2025, all as SVP, Gen Counsel & Corp Sec at Vaxcyte (PCVX), 2022–2025.
The 97 reported transactions were 59 open-market sales, 18 option exercises, 9 tax withholdings and 6 option or other derivative awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 18 sales worth about $6.1M.
The largest open-market sale was 20,000 shares of PCVX at an average $50.40 on October 2, 2023, about $1.0M. Twelve months later PCVX was up 136%.
All 18 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
Shares as reported in the last Form 4 for each company; the most recent is from March 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2025 | PCVX Vaxcyte, Inc. | SVP, Gen Counsel & Corp Sec | Sale+OE10b5-1 | 5,000 | $70.74 | $353,699.01 | -10.7% | -53.1% | -21.3% | |
| Feb 5, 2025 | PCVX Vaxcyte, Inc. | SVP, Gen Counsel & Corp Sec | Sale+OE10b5-1 | 5,000 | $90.07 | $450,368.64 | -15.1% | -67.3% | -39.7% | |
| Jan 6, 2025 | PCVX Vaxcyte, Inc. | SVP, Gen Counsel & Corp Sec | Sale+OE10b5-1 | 5,000 | $85.58 | $427,922.80 | -15.1% | -62.2% | -47.8% | |
| Dec 5, 2024 | PCVX Vaxcyte, Inc. | SVP, Gen Counsel & Corp Sec | Sale+OE10b5-1 | 5,000 | $91.49 | $457,433.92 | -14.8% | -17.9% | -48.4% | |
| Nov 5, 2024 | PCVX Vaxcyte, Inc. | SVP, Gen Counsel & Corp Sec | Sale+OE10b5-1 | 5,000 | $106.36 | $531,803.36 | -14.9% | -21.2% | -62.5% | |
| Oct 7, 2024 | PCVX Vaxcyte, Inc. | SVP, Gen Counsel & Corp Sec | Sale+OE10b5-1 | 5,000 | $109.27 | $546,352.55 | -14.9% | -20.7% | -61.4% | |
| Oct 1, 2024 | PCVX Vaxcyte, Inc. | SVP, Gen Counsel & Corp Sec | Sale+OE10b5-1 | 5,500 | $114.24 | $628,294.76 | -16.1% | -29.0% | -67.1% | |
| Sep 3, 2024 | PCVX Vaxcyte, Inc. | SVP, Gen Counsel & Corp Sec | Sale+OE10b5-1 | 1,667 | $112.11 | $186,879.52 | -5.1% | -16.8% | -70.9% | |
| Aug 1, 2024 | PCVX Vaxcyte, Inc. | SVP, Gen Counsel & Corp Sec | Sale+OE10b5-1 | 1,667 | $78.85 | $131,449.20 | -5.1% | +35.0% | -58.0% | |
| Jul 1, 2024 | PCVX Vaxcyte, Inc. | SVP, Gen Counsel & Corp Sec | Sale+OE10b5-1 | 1,667 | $76.37 | $127,303.98 | -5.1% | +48.5% | -57.2% |